Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicines in Mainland China, Hong Kong, and internationally. More Details
No risks detected for 1666 from our risk checks.
Excellent balance sheet established dividend payer.
Share Price & News
How has Tong Ren Tang Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1666 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1666's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1666 underperformed the Hong Kong Pharmaceuticals industry which returned 20.9% over the past year.
Return vs Market: 1666 underperformed the Hong Kong Market which returned 29.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Tong Ren Tang Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StWhat You Need To Know About Tong Ren Tang Technologies Co. Ltd.'s (HKG:1666) Investor Composition
3 weeks ago | Simply Wall StTong Ren Tang Technologies Co. Ltd.'s (HKG:1666) Intrinsic Value Is Potentially 22% Below Its Share Price
1 month ago | Simply Wall StIs Tong Ren Tang Technologies Co. Ltd. (HKG:1666) A Great Dividend Stock?
Is Tong Ren Tang Technologies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1666 (HK$5.73) is trading below our estimate of fair value (HK$10.32)
Significantly Below Fair Value: 1666 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1666 is poor value based on its PE Ratio (13.2x) compared to the HK Pharmaceuticals industry average (12x).
PE vs Market: 1666 is poor value based on its PE Ratio (13.2x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: 1666 is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: 1666 is good value based on its PB Ratio (1.1x) compared to the HK Pharmaceuticals industry average (1.3x).
How is Tong Ren Tang Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1666's forecast earnings growth (8.5% per year) is above the savings rate (1.5%).
Earnings vs Market: 1666's earnings (8.5% per year) are forecast to grow slower than the Hong Kong market (18.8% per year).
High Growth Earnings: 1666's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1666's revenue (7.9% per year) is forecast to grow slower than the Hong Kong market (13.4% per year).
High Growth Revenue: 1666's revenue (7.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1666's Return on Equity is forecast to be low in 3 years time (8.5%).
How has Tong Ren Tang Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1666 has high quality earnings.
Growing Profit Margin: 1666's current net profit margins (10.1%) are higher than last year (9.3%).
Past Earnings Growth Analysis
Earnings Trend: 1666's earnings have declined by 7% per year over the past 5 years.
Accelerating Growth: 1666's earnings growth over the past year (12.1%) exceeds its 5-year average (-7% per year).
Earnings vs Industry: 1666 earnings growth over the past year (12.1%) exceeded the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: 1666's Return on Equity (10.1%) is considered low.
How is Tong Ren Tang Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: 1666's short term assets (CN¥7.5B) exceed its short term liabilities (CN¥2.5B).
Long Term Liabilities: 1666's short term assets (CN¥7.5B) exceed its long term liabilities (CN¥734.4M).
Debt to Equity History and Analysis
Debt Level: 1666's debt to equity ratio (19.9%) is considered satisfactory.
Reducing Debt: 1666's debt to equity ratio has increased from 3.5% to 19.9% over the past 5 years.
Debt Coverage: 1666's debt is well covered by operating cash flow (53%).
Interest Coverage: 1666's interest payments on its debt are well covered by EBIT (394.9x coverage).
What is Tong Ren Tang Technologies's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1666's dividend (3.32%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.96%).
High Dividend: 1666's dividend (3.32%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).
Stability and Growth of Payments
Stable Dividend: 1666's dividends per share have been stable in the past 10 years.
Growing Dividend: 1666's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (43.8%), 1666's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1666's dividends in 3 years are forecast to be well covered by earnings (43.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yu Wang (49 yo)
Mr. Yu Wei Wang serves as Secretary of the Board at Aerospace Hi-Tech Holding Group Co., Ltd. (alternate name: Harbin Fenghua-Aerospace Hi-Tech Co. Ltd.). Mr. Wang has been the General Manager at Tong Ren ...
CEO Compensation Analysis
Compensation vs Market: Yu's total compensation ($USD329.11K) is about average for companies of similar size in the Hong Kong market ($USD440.00K).
Compensation vs Earnings: Yu's compensation has been consistent with company performance over the past year.
Experienced Management: 1666's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: 1666's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tong Ren Tang Technologies Co. Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Tong Ren Tang Technologies Co. Ltd.
- Ticker: 1666
- Exchange: SEHK
- Founded: 1669
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$7.339b
- Shares outstanding: 1.28b
- Website: https://www.tongrentangkj.com
Number of Employees
- Tong Ren Tang Technologies Co. Ltd.
- No. 20 Nansanhuan Zhonglu Road
- Fengtai District
Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicines in Mainland China, Hong Kong, and internationally. It offers its products in the form of tablets, soft capsules, concentrated pi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 10:24|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.